GCGR and type 1 diabetes mellitus: GCGR antagonism has been proposed as a pharmacological approach to treat T1D or T2D, including the use of small molecule antagonists, monoclonal antibodies (mAb) against GCGR, and antisense oligonucleotides that reduce expression of the receptor (70–73).